Skip to content
Gene2Rx home

Try

Loading…

Search couldn't load. Check your connection and try again, or use the medication lookup.

No pages match .

The medication lookup checks any medication by name, including ones without their own page.

Get my report
In the Full Report Needs whole genome data

Methoxyflurane, Genetics, and Malignant Hyperthermia

Methoxyflurane is one of the potent volatile anesthetics that CPIC names as malignant hyperthermia (MH) triggers [1]. It was once used as a general anesthetic. Today, as Penthrox in the UK, it is a low-dose inhaled pain reliever for trauma pain, breathed in from a handheld inhaler, and even this analgesic product is contraindicated in people known to be, or genetically, susceptible to MH [2].

At a glance
Brand namesPenthrox
Used forEmergency relief of moderate to severe trauma pain in conscious patients aged 6 and older (UK licence)
GenesRYR1, CACNA1S
GuidanceCPIC guideline (2019) [1]; UK summary of product characteristics (section 4.3) [2]
Gene2Rx coverageWhole-genome sequencing only. RYR1 and CACNA1S are not assessed from consumer DNA tests such as 23andMe or AncestryDNA.

How methoxyflurane works

The UK summary of product characteristics (SmPC) for Penthrox describes a 3 mL dose, self-administered under supervision through a handheld inhaler, with pain relief starting after 6 to 10 breaths in adults. A second 3 mL bottle can be used if needed, but not more than 6 mL in a day or 15 mL in a week, and use on consecutive days is not recommended. Penthrox must not be used as an anesthetic [2].

Methoxyflurane is metabolized in the liver, mainly by CYP2E1 and CYP2B6 and to some extent CYP2A6, to fluoride, oxalic acid and other products. At the high doses once used for anesthesia, fluoride levels above 40 micromol/L caused serious kidney damage; a single 3 mL analgesic dose keeps fluoride below 10 micromol/L. The SmPC advises avoiding drugs that speed up these enzymes (such as alcohol, isoniazid, phenobarbital, rifampicin, carbamazepine, efavirenz and nevirapine) and notes that people whose genetic make-up makes them fast metabolizers may face more toxicity [2]. No guideline translates CYP2B6 or CYP2A6 genotype into methoxyflurane advice, and Gene2Rx gives none.

The SmPC contraindicates methoxyflurane in people known to be, or genetically, susceptible to MH and in people with a family history of severe reactions to inhaled anesthetics [2].

How RYR1 and CACNA1S cause malignant hyperthermia

Every skeletal muscle contraction starts with calcium. When a nerve signal reaches a muscle fiber, a voltage sensor in the cell membrane, mechanically linked to a calcium channel on the fiber's internal store, opens that channel. The CACNA1S gene makes the main part of that voltage sensor (the dihydropyridine receptor). The RYR1 gene makes the calcium channel itself, ryanodine receptor 1 [1].

MH-associated variants, usually a single amino-acid change in one copy of the gene, make the RYR1 channel easier to open. Most carriers have no symptoms until they meet a trigger. A potent volatile anesthetic or succinylcholine can then cause a sustained rise of calcium inside the muscle, and the fibers contract uncontrollably. CPIC lists the earliest signs as a fast heart rate and a rise in exhaled carbon dioxide, followed by muscle rigidity, acidosis, high blood potassium, rising body temperature and abnormal heart rhythms. When succinylcholine is given, jaw muscle rigidity is often the first sign. Untreated, the reaction can end in cardiac arrest and death [1].

The CPIC guideline gives these figures [1]:

  • MH reactions occur in an estimated 1 in 10,000 to 1 in 250,000 anesthetics.
  • The inherited susceptibility is estimated to affect 1 in 2,000 to 1 in 3,000 people.
  • RYR1 accounts for about 70% of people with known susceptibility, and CACNA1S for about 1%.
  • The genetic cause is still unknown in about half of MH survivors whose susceptibility was confirmed by a contracture test.
  • An unexpected reaction can carry a complication rate as high as 35%, and a fulminant reaction a mortality of 12%.

RYR1 is a large gene: more than 2,700 coding variants had been recorded when the guideline was written, and separating harmful ones from harmless ones takes many kinds of evidence. CPIC therefore lists the specific variants with enough evidence to be called MH-associated. The 2019 guideline started from 48 RYR1 and 2 CACNA1S variants accepted as diagnostic by the European Malignant Hyperthermia Group [1]. CPIC's current allele tables list 96 RYR1 variants and 2 CACNA1S variants as "Malignant Hyperthermia associated", and they list another 216 RYR1 variants as "uncertain function" [3] [4]. There are no star alleles or metabolizer groups. One copy of a listed variant is enough for CPIC to presume susceptibility.

A diagnosis of MH susceptibility can be made in two ways. One is a muscle biopsy tested with caffeine and halothane in the laboratory, called the in vitro contracture test (IVCT) or, in the United States, the caffeine-halothane contracture test (CHCT). The other is finding a pathogenic RYR1 or CACNA1S variant. The biopsy test is done only at specialized centers. CPIC describes its sensitivity as high, so a negative contracture test rules out the diagnosis [1].

What the guidelines recommend

The Clinical Pharmacogenetics Implementation Consortium (CPIC) published its guideline on RYR1, CACNA1S, potent volatile anesthetics and succinylcholine in 2019 [1]. It names the triggering agents as the potent volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane and sevoflurane) and the depolarizing muscle relaxant succinylcholine, and treats all of the volatile agents as equivalent triggers. Nitrous oxide, xenon, intravenous anesthetics and non-depolarizing muscle relaxants are not linked to MH.

For a person with a listed variant, CPIC calls the triggering agents relatively contraindicated: they should not be used except in extraordinary circumstances where the benefits outweigh the risks. The recommended alternatives are regional anesthesia (a nerve block, spinal or epidural, or local anesthesia) or general anesthesia with non-triggering agents, given through equipment that has been flushed of volatile anesthetic. Both of CPIC's recommendations are rated strong. The guideline is written for people with no known personal or family history of MH and no muscle disease who are found to carry a listed variant. Diagnostic evaluation, relatives of a known MH family who test negative, and people with RYR1-related myopathies fall outside it [1].

RYR1 and CACNA1S results and triggering anesthetics
ResultWhat it meansGuideline recommendation
Malignant Hyperthermia SusceptibilityA CPIC-listed MH-associated variant was found in RYR1 or CACNA1S. The person is at increased risk of MH if given a potent volatile anesthetic or succinylcholine.CPIC (strong): these agents are relatively contraindicated and should not be used except in extraordinary circumstances where benefits outweigh risks. Alternative anesthetics are widely available and effective.
No known risk variants foundNo listed MH-associated variant, and no variant of uncertain effect, was found in the WGS data. This does not remove the chance of MH susceptibility. CPIC calls this result Uncertain Susceptibility.CPIC (strong): clinical findings, family history, further genetic testing and other laboratory data should guide the use of these agents.
Uncertain SusceptibilityNo listed MH-associated variant was found, but the WGS data carries a listed variant whose effect on MH is not known, such as one CPIC classes as uncertain function.CPIC (strong): clinical findings, family history, further genetic testing and other laboratory data should guide the use of these agents.
Unable to determine (No Result)WGS data was supplied, but it could not give a reliable result: for example, a call at a listed position failed quality checks or conflicted with another record. This is not a negative result.Gene2Rx: clinical findings, family history and clinical evaluation should guide anesthesia decisions.
Not assessedThe data came from a consumer genotyping array, which this screen does not use. This is not a negative result.Gene2Rx: as above, the decision rests on clinical findings and history.

A susceptibility result for either gene leads to the same recommendation. When one gene shows susceptibility and the other is uncertain or has no result, the report still gives the susceptibility recommendation. The "Indeterminate" and "Not available" labels used for some other genes do not occur here, because the MH screen does not produce them.

Want to know what your genetics say about how you'll respond to Methoxyflurane?

A Gene2Rx report reads your own DNA to show how it may affect your response to Methoxyflurane and your other medications.

Using your result

The anesthesia team chooses the anesthetic, and a genetic report should not be used to steer that choice on its own. What a result can do is start the conversation early, ideally at the pre-operative visit rather than on the day of surgery.

If your report shows malignant hyperthermia susceptibility

Give the anesthesia team the report page that names the variant, with its gene, position and protein change. Under the CPIC guideline, a person carrying a listed MH-associated variant is presumed susceptible, and only non-triggering agents should be used [1]. Gene2Rx is not a clinical laboratory, so ask your clinician to confirm the variant with a clinical-grade test. A confirmed result belongs in the medical record and gives relatives a defined variant to test for.

MH susceptibility is inherited in an autosomal dominant pattern: each child of a susceptible parent has a 50% chance of carrying the variant. CPIC advises evaluating all at-risk relatives, including children, with an expert in the genetics of MH. If the father of an expected baby is susceptible, CPIC recommends non-triggering agents should the pregnant mother need general anesthesia. Some MH-associated RYR1 variants also occur in RYR1-related muscle diseases, which need a neuromuscular specialist and are outside the guideline's scope [1].

If your report says no known risk variants were found

Listed variants are rare, so most people with WGS data get this result: the screen checked RYR1 and CACNA1S and found none of the variants CPIC lists. It is not an all-clear. CPIC states that the absence of a listed variant does not lower the chance of an MH event compared with the general population [1]. If your report shows uncertain susceptibility instead, the screen found a variant whose effect on MH is not yet known; share that finding with the anesthesia team too. Either way, tell the team about any of these, whatever the genetic result says:

  • a previous reaction under anesthesia, such as a high fever, jaw muscle stiffness or another reaction that was never explained
  • a relative who had a reaction, died unexpectedly during surgery, or was told they are MH susceptible
  • a diagnosed muscle disease

CPIC asks the clinician to weigh personal and family history, any earlier genetic or contracture testing, and other findings [1]. Where the history raises concern, the next step is a specialist referral. The Malignant Hyperthermia Association of the United States (MHAUS) describes two kinds of diagnostic testing, genetic testing and a muscle biopsy contracture test, and advises talking with a genetic counselor about which one fits [5].

Other medicines

Other medicines can shift many drug-gene results by blocking or speeding up a drug-processing enzyme. That does not apply here. RYR1 and CACNA1S variants change how muscle responds to the triggering drugs, not how fast the drugs are cleared, so the guidance concerns which agents are used rather than the dose [1].

What this result cannot tell you

The Gene2Rx malignant hyperthermia screen runs only on original whole-genome sequencing files (VCF). Consumer arrays such as 23andMe, AncestryDNA and MyHeritage do not receive it. MH variants are rare, and inferring them from array data by imputation is not reliable enough, so array reports show this assessment as not assessed. That is not a negative result.

With WGS data, the screen checks the positions in CPIC's allele tables and nothing else [3] [4]. It does not classify new or unlisted variants, and it does not look at other genes linked to MH, such as STAC3. Every variant the screen checks, and how it calls them is written up for anesthesia teams. Many VCF files list only the positions where a variant was found. When a listed position is missing from the file, Gene2Rx cannot confirm that the sequencing covered it, so it does not count the position as normal: the report notes the gap, and a screen that finds nothing reads "no known risk variants found", never a normal result. If a listed position is present but its call fails quality checks or conflicts with another record, the result is "unable to determine".

The guideline's own caveat is the larger limit. Testing for listed variants has a high positive predictive value but poor sensitivity: a found variant is meaningful, while a negative result rules out very little [1]. A past anesthetic without a reaction does not settle the question either, because CPIC notes that not every exposure of a susceptible person to a triggering agent leads to a reaction.

A Gene2Rx report is not a clinical test. For anesthesia planning, the right basis is a clinical genetic test or a contracture test at an MH testing center, interpreted together with personal and family history [1] [5].

Common questions

Is the low analgesic dose safe for someone with MH susceptibility?

The product information says no: Penthrox is contraindicated in people who are known to be, or genetically, susceptible to MH, and in people with a family history of severe reactions to inhaled anesthetics [2]. Tell the clinician offering it about any such history.

My report shows a CYP2B6 or CYP2A6 result. Does it apply to methoxyflurane?

Not directly. These enzymes help break down methoxyflurane, and the SmPC mentions fast metabolizers as a possible risk group [2], but no guideline gives genotype-based advice and the Gene2Rx report does not apply those results to methoxyflurane.

Is methoxyflurane still used as a general anesthetic?

No. The SmPC describes its anesthetic use in the past tense and contraindicates Penthrox as an anesthetic agent [2].

Sources and further reading

  1. Gonsalves SG et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes. Clin Pharmacol Ther (2019). Mechanism, frequencies, diagnosis, recommendations and their scope, family and pregnancy advice, limits of negative results.
  2. Penthrox 99.9%, 3 ml inhalation vapour, liquid: summary of product characteristics. Electronic Medicines Compendium (UK). Indication, dosing, contraindications including MH, kidney and liver warnings, metabolism and interactions.
  3. CPIC. RYR1 allele functionality table (spreadsheet). Current list of RYR1 variants and their clinical function.
  4. CPIC. CACNA1S allele functionality table (spreadsheet). Current list of CACNA1S variants and their clinical function.
  5. Malignant Hyperthermia Association of the United States. Introduction to MH testing. Genetic testing and muscle biopsy testing, and the advice to consult a genetic counselor.

This page explains pharmacogenetic evidence. Clinical decisions depend on your medical history, other medicines, and a qualified clinician's assessment.